PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
111.14%
Growth of 111.14% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
161.14%
Cost growth of 161.14% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify cost control.
91.08%
Growth of 91.08% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
-9.50%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-37.31%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
51.24%
G&A change of 51.24% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
55.33%
Marketing expense change of 55.33% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
47.21%
Other expenses change of 47.21% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
46.87%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for waste.
67.95%
Total costs change of 67.95% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
-22.41%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
11.97%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.08%. Jim Chanos would check for overinvestment.
16.70%
EBITDA change of 16.70% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
60.55%
Margin change of 60.55% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
10.33%
Income change of 10.33% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
57.53%
Margin change of 57.53% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-9.02%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
10.46%
Income change of 10.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
57.59%
Margin change of 57.59% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-3279660318548.25%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
10.46%
Income change of 10.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
57.59%
Margin change of 57.59% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
10.98%
EPS change of 10.98% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
10.98%
Diluted EPS change of 10.98% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-1.98%
Share count reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate strategy.
0.00%
Diluted share change of 0.00% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.